电描记流一致性对心房颤动复发与基质状态的表征
本文基于FLOW-AF等三项临床试验,分析电描记流一致性(EGFC)在心房颤动患者中的预后价值。结果显示,平均双房EGFC<0.62可较好预测无源及治疗组患者的房颤复发。EGFC与复发风险及部分临床类型相关,或可辅助房颤患者表型分型。
要点
- 平均双房EGFC<0.62可预测FLOW-AF无源及治疗组房颤复发。
- EGFC≥0.62者复发率低于EGFC<0.62者。
- EGFC不受PVI或消融源清除影响,或反映心房基质健康。
核心结论
- 平均双房EGFC<0.62是预测FLOW-AF无源及治疗组房颤复发的最佳指标。
- EGFC可能反映心房基质健康,并可辅助基于机制与复发风险的房颤表型分型。
研究设计与样本
- 研究纳入三项临床试验中使用64电极篮状导管记录单极电图的房颤患者。
- 采用EGF算法重建波前传播模式,并计算每个患者的平均EGFC。
- 将EGFC与12个月无房颤生存、患者人口学因素及双极电压标测数据进行比较。
主要发现
- 在无源和治疗组患者中,EGFC≥0.62者的复发率为6%,EGFC<0.62者为51%;p<0.001。
- 术后仍有源的控制组患者中,对应EGFC组的复发率分别为77%和100%;p=0.032。
- 在103±22天后重复标测的亚组中,EGFC从0.58±0.15降至0.51±0.14;配对p=0.041。
- EGFC不受肺静脉隔离或源消融影响;配对p>0.30。
- 新发和阵发性房颤患者的EGFC分别高于再发患者(p=0.043)和非阵发性房颤患者(p=0.022)。
关键数值与推荐
- 平均双房EGFC<0.62在五折交叉验证后预测复发的准确性为86%±11%。
- 无源及治疗组中,EGFC≥0.62者复发率为6%,EGFC<0.62者为51%;p<0.001。
- 术后有源的控制组中,对应EGFC组的复发率分别为77%和100%;p=0.032。
- 重复标测亚组中,EGFC从0.58±0.15降至0.51±0.14;配对p=0.041。
临床怎么用
- EGFC可辅助判断房颤患者术后复发风险,并帮助区分不同疾病机制的表型。
- 不能仅凭单次PVI或源消融后的EGFC变化来评价消融效果。
局限性
- 部分亚组的样本量及事件数可能有限,影响统计稳定性。
- 重复标测分析仅在一个亚组中进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Electrographic flow (EGF) mapping is an FDA 510(k)-cleared method for visualizing atrial activation wavefronts in atrial fibrillation (AF). Its clinical efficacy in detecting AF sources was demonstrated in the FLOW-AF randomized controlled trial, and the underlying machine learning strategy used to develop and refine EGF source detection has been recently detailed. However, EGF mapping metrics can also characterize other properties of atrial wavefront propagation—most notably Electrographic Flow Consistency (EGFC) as a measure of the health of the atrial substrate. Patients with low EGFC have been found to have recurrent AF more frequently than those with high EGFC. EGFC may therefore be additive to source presence to phenotype AF patients based on mechanism of disease and recurrence likelihood. Objectives Present the EGFC-based Kaplan–Meier curves for each study arm of FLOW-AF and explore the clinical relevance of EGFC using prospective studies. Methods Unipolar electrograms were recorded using 64-electrode basket catheters in AF patients across three clinical trials. The EGF algorithm then processed these recordings to reconstruct wavefront propagation patterns. EGFC was quantified from the vector length at each point in space and averaged across spatial coordinates and mapping positions to determine the mean EGFC for each patient. As applicable, EGFC and related EGF map characteristics were compared with 12-month freedom from AF, patient demographic factors, and bipolar voltage mapping data. Results Primarily, mean biatrial EGFC < 0.62 was found to be the best metric at predicting recurrent AF in No Source and Treatment patients in FLOW-AF: it had 86% ± 11% accuracy after fivefold cross-validation. Among these patients, those with EGFC ≥ 0.62 had 6% recurrence vs. 51% recurrence in those with EGFC < 0.62; p < 0.001. Control patients with sources post-procedure had 77% vs. 100% recurrence in respective EGFC groups; p = 0.032. Follow-up analyses showed that EGFC dropped from 0.58 ± 0.15 to 0.51 ± 0.14 (paired p = 0.041) in a subgroup of patients who underwent repeat mapping 103 ± 22 days later, but it was not affected by pulmonary vein isolation (PVI) or source ablation (paired p > 0.30). It was also higher among de novo and paroxysmal AF patients than redo (p = 0.043) and non-paroxysmal AF patients (p = 0.022), respectively. Among the group of patients with low EGFC and no sources post-procedure, recurrent patients had increased EGFC
引用
- Journal of Cardiovascular Electrophysiology:Characterization of AF Recurrence and Substrate Health by Electrographic Flow (EGF) Consistency in EGF Mapping
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。